Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

VISOR for removing 1–3 cm kidney and ureter stones

Official title: A Single-Center Clinical Study on the Efficacy and Safety of Vortex Intelligence Stone Optimized Removal (VISOR)

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07071948 · Data updated 2026-11-12

This will test a new device called VISOR to break up and remove 1–3 cm kidney or ureter stones in adults aged 18–80.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment20 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedAugust 6, 2025
Main results expectedOctober 31, 2025
Study endsFebruary 28, 2027
Registry record updatedSeptember 26, 2025
Trial IDNCT07071948 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with upper urinary tract stones totaling 1–3 cm who opt for flexible ureteroscopic holmium laser lithotripsy and can give informed consent are ideal candidates.

Probably not a fit

Patients with ureteral strictures, prior open or laparoscopic renal/ureter surgery, recent fever from infection, pregnant or lactating women, or those with ASA class >3 are excluded and unlikely to benefit in this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study uses the VISOR multifunctional integrated flexible ureteroscope during flexible ureteroscopic holmium laser lithotripsy to break and remove upper urinary tract stones 1–3 cm in size. During surgery VISOR's features—flushing/suction, pressure control, and simultaneous stone fragmentation/removal—are used and intrarenal pressure is monitored to keep it below 30 mmHg. Success is defined as stone fragments <4 mm on a CT scan obtained within 24 hours after surgery, and safety is tracked by recording serious complications through a 4-week follow-up visit. The trial aims to see if at least 90% of participants are stone-free within 24 hours and if serious adverse events occur in no more than 5% of cases.

Why it matters

Potential benefit: If successful, VISOR could increase the share of patients who are quickly stone-free after ureteroscopic surgery while reducing pressure-related complications.

How similar studies have gone: Some ureteroscopes with suction and pressure-control features have shown promising results in small studies, but VISOR's particular combination of functions is relatively new and less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm
2. Patients who choose to undergo "flexible ureteroscopic holmium laser lithotripsy"
3. Aged 18-80 years, regardless of gender
4. Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form

Exclusion Criteria:

1. Patients with ureteral stricture or a history of ureteral stricture
2. Patients with a history of open renal and/or ureteral surgery or laparoscopic surgery
3. Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery
4. Pregnant women, lactating women, or women who are in the menstrual period
5. ASA classification \> Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery
6. Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney
7. Patients with abnormal coagulation function (e.g., international normalized ratio (INR) \> 1.5 or platelet count \< 80 × 10⁹/L)
8. Patients with failed sheath placement during surgery

Where it's running

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Bohan Wang, MD., Ph.D — 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  • Study coordinator: Bohan Wang, MD., Ph.D
  • Email: wangbohan@zju.edu.cn
  • Phone: +86-13575799866

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.